FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977492077> ?p ?o ?g. }

• W2977492077 endingPage "S4" @default.
• W2977492077 startingPage "S4" @default.
• W2977492077 abstract "Purpose: A previous large study showed that esomeprazole more effectively healed erosive esophagitis (EE) across all Los Angeles (LA) grades than lansoprazole; the largest difference was seen for LA grades C and D.1 The purpose of this study was to compare oral esomeprazole 40 mg once daily with lansoprazole 30 mg once daily for healing moderate to severe EE and to confirm the results in the subgroup of patients with moderate or severe EE from the previous trial. Methods: Patients with moderate or severe EE (LA grades C or D) confirmed by endoscopy were enrolled into a multicenter, randomized, double-blind, double-dummy, parallel-group study (D9612L00046/Study 322) that was part of a total patient management program. Patients received esomeprazole 40 mg or lansoprazole 30 mg once daily for up to 8 weeks. Endoscopy was performed at week 4; patients without complete healing continued treatment for an additional 4 weeks when a final endoscopy was performed. The primary efficacy variable was the healing status of EE, healed or unhealed, during the 8-week study period. The percentage of healed patients was calculated using the Kaplan-Meier method. A log-rank test was used to compare treatments for the EE healing rate. The investigator evaluated heartburn severity at each clinical visit; “resolution” of heartburn was defined as symptom severity of “none” on a 4-point scale. A Cochran-Mantel-Haenszel test, stratified by baseline symptom severity, was used to compare the difference in heartburn resolution between treatment groups. Results: The estimated healing rates are shown in the Table. More patients achieved resolution of heartburn at week 4 with esomeprazole than with lansoprazole (72% vs 64%; P = .005).Table: Estimated Healing RatesConclusions: Esomeprazole 40 mg once daily was more effective than lansoprazole 30 mg once daily in healing moderate to severe EE through 8 weeks of therapy and in resolving heartburn through 4 weeks of therapy." @default.
• W2977492077 created "2019-10-10" @default.
• W2977492077 creator A5016255188 @default.
• W2977492077 creator A5018989715 @default.
• W2977492077 creator A5031863162 @default.
• W2977492077 creator A5047243765 @default.
• W2977492077 creator A5087794393 @default.
• W2977492077 date "2004-10-01" @default.
• W2977492077 modified "2023-09-23" @default.
• W2977492077 title "ESOMEPRAZOLE 40 MG VERSUS LANSOPRAZOLE 30 MG IN HEALING AND SYMPTOM RELIEF IN PATIENTS WITH MODERATE TO SEVERE EROSIVE ESOPHAGITIS (LOS ANGELES GRADES C OR D)" @default.
• W2977492077 doi "https://doi.org/10.14309/00000434-200410001-00011" @default.
• W2977492077 hasPublicationYear "2004" @default.
• W2977492077 type Work @default.
• W2977492077 sameAs 2977492077 @default.
• W2977492077 citedByCount "1" @default.
• W2977492077 crossrefType "journal-article" @default.
• W2977492077 hasAuthorship W2977492077A5016255188 @default.
• W2977492077 hasAuthorship W2977492077A5018989715 @default.
• W2977492077 hasAuthorship W2977492077A5031863162 @default.
• W2977492077 hasAuthorship W2977492077A5047243765 @default.
• W2977492077 hasAuthorship W2977492077A5087794393 @default.
• W2977492077 hasConcept C126322002 @default.
• W2977492077 hasConcept C141071460 @default.
• W2977492077 hasConcept C168563851 @default.
• W2977492077 hasConcept C2776462128 @default.
• W2977492077 hasConcept C2777498785 @default.
• W2977492077 hasConcept C2778204628 @default.
• W2977492077 hasConcept C2778451229 @default.
• W2977492077 hasConcept C2778715759 @default.
• W2977492077 hasConcept C2779134260 @default.
• W2977492077 hasConcept C2779920096 @default.
• W2977492077 hasConcept C43270747 @default.
• W2977492077 hasConcept C71924100 @default.
• W2977492077 hasConcept C90924648 @default.
• W2977492077 hasConceptScore W2977492077C126322002 @default.
• W2977492077 hasConceptScore W2977492077C141071460 @default.
• W2977492077 hasConceptScore W2977492077C168563851 @default.
• W2977492077 hasConceptScore W2977492077C2776462128 @default.
• W2977492077 hasConceptScore W2977492077C2777498785 @default.
• W2977492077 hasConceptScore W2977492077C2778204628 @default.
• W2977492077 hasConceptScore W2977492077C2778451229 @default.
• W2977492077 hasConceptScore W2977492077C2778715759 @default.
• W2977492077 hasConceptScore W2977492077C2779134260 @default.
• W2977492077 hasConceptScore W2977492077C2779920096 @default.
• W2977492077 hasConceptScore W2977492077C43270747 @default.
• W2977492077 hasConceptScore W2977492077C71924100 @default.
• W2977492077 hasConceptScore W2977492077C90924648 @default.
• W2977492077 hasLocation W29774920771 @default.
• W2977492077 hasOpenAccess W2977492077 @default.
• W2977492077 hasPrimaryLocation W29774920771 @default.
• W2977492077 hasRelatedWork W1981949716 @default.
• W2977492077 hasRelatedWork W2006599150 @default.
• W2977492077 hasRelatedWork W2039710754 @default.
• W2977492077 hasRelatedWork W2043054250 @default.
• W2977492077 hasRelatedWork W2082746732 @default.
• W2977492077 hasRelatedWork W2356848596 @default.
• W2977492077 hasRelatedWork W2361165765 @default.
• W2977492077 hasRelatedWork W2372910640 @default.
• W2977492077 hasRelatedWork W2414580964 @default.
• W2977492077 hasRelatedWork W3139981236 @default.
• W2977492077 hasVolume "99" @default.
• W2977492077 isParatext "false" @default.
• W2977492077 isRetracted "false" @default.
• W2977492077 magId "2977492077" @default.
• W2977492077 workType "article" @default.